PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. RESEARCH DESIGN AND METHODS: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA1c. The confirmatory secondary end point was change from baseline to week 26 in body weight. RESULTS: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA1c 8.0% [64 mmol/mol]), oral semaglutide reduced HbA1c (placebo-adjusted treatment differences at week 26: treatment policy estimand, −0.6% [3 mg], −0.9% [7 mg], and −1.1% [14 mg]; trial product estimand, −0.7% [3 mg], −1.2% [7 mg], and −1.4% [14 mg]; P < 0.001 for all) and body weight (treatment policy, −0.1 kg [3 mg], −0.9 kg [7 mg], and −2.3 kg [14 mg, P < 0.001]; trial product, −0.2 kg [3 mg], −1.0 kg [7 mg, P = 0.01], and −2.6 kg [14 mg, P < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3–7.4% with oral semaglutide and 2.2% with placebo. CONCLUSIONS: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapies shown to positively affect albuminuria and declining eGFR include ACE inhibitors, ARBs, SGLT2is, GLP-1 RAs, and the nonsteroidal mineralocorticoid antagonist finerenone.197,209,239,242,393,423–435”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin and canagliflozin demonstrated reduction in MACE in CVOTs; empagliflozin also demonstrated decreased CV death and all-cause mortality.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have shown a decrease in hospitalization for HF in their CVOTs.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Dapagliflozin based on the DAPA-CKD RCT424 has received an FDA indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for HF in adults with CKD at risk of progression.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Multiple studies have shown renal and CV benefits of SGLT2is239,424–426,444,1052–1054”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†Severe hypoglycemia was defined according to the American Diabetes Association classification (16) (requiring assistance of another person to actively administer carbohydrateor glucagonor takeother correctiveactions).”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 2×
“The safety profile of oral semaglutide was generally consistent with that reported for subcutaneous semaglutide (19)”
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Cited by
Items 101–200 of 538
Cowart, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028019889064 · Cited by 42
Xia, L., Shen, T., Dong, W., Su, F., Wang, J., Wang, Q., Niu, S., & Fang, Y. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108904 · Cited by 40
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Kalra, S., Bhattacharya, S., & Kapoor, N. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01113-y · Cited by 38
Zaazouee, M. S., Hamdallah, A., Helmy, S. K., Hasabo, E. A., Sayed, A. K., Gbreel, M. I., Elmegeed, A. A., Aladwan, H., Elshanbary, A. A., Abdel‐Aziz, W., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102511 · Cited by 45
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
Li, J., He, K., Ge, J., Li, C., & Jing, Z. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108656 · Cited by 40
Kim, H. S., & Jung, C. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189936 · Cited by 45
“Sci. 2021, 22, 9936 8 of 12 subcutaneous GLP-1RAs for T2D, this study suggested the long-term (52-week) efficacy and safety of oral semaglutide versus subcutaneous liraglutide.”
BackgroundResultInfluentialAlhindi, Y., & Avery, A. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100944 · Cited by 37
Why estimands are needed to define treatment effects in clinical trials
Keene, O. N., Lynggaard, H., Englert, S., Lanius, V., & Wright, D. N. M. (2023) · BMC Medicine · doi:10.1186/s12916-023-02969-6 · Cited by 39
“For example, PIONEER-1 [5] compared the effects of semaglutide with placebo on glycaemic control in patients with type 2 diabetes mellitus.”
InfluentialOral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 41
“Compared with active drugs, oral semaglutide was superior to empagliflozin in reducing total cholesterol and LDL [36] and was superior to sitagliptin in reducing total cholesterol, LDL, Ta bl e 1 G LP -1 re ce pt or a go ni st s: ca rd io va sc ul ar in di ca tio ns a nd C VO Ts re su lts CV c ar di ov as cu la r, CV…”
BackgroundMethodInfluentialKick, A., M'Rabet‐Bensalah, K., Acquistapace, F., Amadid, H., Ambühl, R. A., Braae, U. C., Item, F., Schultes, B., Züger, T., & Rudofsky, G. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01525-y · Cited by 41
“The safety and tolerability of oral semaglu-tide were similar to that previously reported in phase 3 trials, with gastrointestinal effects, especially nausea and vomiting, being the most frequently reported AEs [13–15, 17, 18, 22, 23].”
Buse, J. B., Bode, B. W., Mertens, A., Cho, Y. M., Christiansen, E., Hertz, C. L., Nielsen, M. A., & Pieber, T. R. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001649 · Cited by 38
Self-citationHauge, C., Breitschaft, A., Hartoft‐Nielsen, M., Jensen, S., & Bækdal, T. A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1955856 · Cited by 41
“98] Cmax, ng/mL [95% CI] 1,078 [928; 1,253] 1,387 [1,194; 1,612] Estimated treatment ratio (co-administered/alone) [95% CI] 1.”
Wang, W., Bain, S. C., Bian, F., Chen, R., Gabery, S., Huang, S., Jensen, T. B., Luo, B., Yuan, G., Ning, G., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06142-3 · Cited by 35
Hansen, B. B., Nuhoho, S., Ali, S. N., Dang-Tan, T., Valentine, W. J., Malkin, S. J. P., & Hunt, B. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1722678 · Cited by 36
Wright, E. E., & Aroda, V. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798127 · Cited by 47
Self-citationHui, E. K., Mukadam, N., Kohl, G., & Livingston, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251319054 · Cited by 39
A Review on the Efficacy and Safety of Oral Semaglutide
Niman, S., Hardy, J., Goldfaden, R. F., Reid, J., Sheikh‐Ali, M., SUTTON, D. R., & Choksi, R. R. (2021) · Drugs in R&D · doi:10.1007/s40268-021-00341-8 · Cited by 43
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A. M., Sadhu, A., Valencia, C., Fatima, H., & Nwankwo, I. (2022) · Cureus · doi:10.7759/cureus.32610 · Cited by 35
Dutta, D., Nagendra, L., Anne, B., Kumar, M., Sharma, M., & Kamrul‐Hasan, A. B. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.743 · Cited by 35
“8 However, the weight loss observed with oral semaglutide, 14 mg taken orally daily, is lower than that of injectable semaglutide.”
BackgroundTseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Buckeridge, C., Cobain, S., Bays, H. E., Matsuoka, O., Fukushima, Y., Halstead, P., Tsamandouras, N., Sherry, N., Gorman, D. N., & Saxena, A. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16534 · Cited by 38
Self-citationClinical potential of treatment with semaglutide in type 2 diabetes patients
Røder, M. E. (2019) · Drugs in Context · doi:10.7573/dic.212585 · Cited by 37
Barrea, L., Pugliese, G., Muscogiuri, G., Laudisio, D., Colao, A. A. L., & Savastano, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03179-x · Cited by 38
Advances in GLP-1 treatment: focus on oral semaglutide
Eliaschewitz, F. G., & Canani, L. H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00713-9 · Cited by 34
“PIONEER trials 1, 5, and 8 evaluated the effects of oral semaglutide in comparison with placebo [39, 43, 46].”
BackgroundCleto, A. S., Schirlo, J. M., Beltrame, M. L., Gomes, V. H. O., Acras, I. H., Neiverth, G. S., da Silva, B. B., Juliatto, B. M. S., Machozeki, J., & Martins, C. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01646-9 · Cited by 37
“Therefore, despite this limitation, there was no difference in the result.”
Bell, J., Drury, T., Mütze, T., Pipper, C. B., Guizzaro, L., Mitroiu, M., Rantell, K. R., Wolbers, M., & Wright, D. D. (2025) · Pharmaceutical Statistics · doi:10.1002/pst.2472 · Cited by 33
“The methods were assessed using a simulation study designed to mimic the outcomes, IEs and missingness of the Phase 3 PIONEER1 [20] randomized clinical trial as a base case, with more extreme missingness scenarios also created.”
InfluentialRen, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 35
Wan, J., Ferrari, C., & Tadros, M. S. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15010014 · Cited by 34
“For oral semaglutide, the occurrence rates were 5.1 to 23.2% for nausea, 2.9 to 9.9% for vomiting, and 5.1 to 15% for diarrhea during the on-treatment period [54–56].”
BackgroundInfluentialAllocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 37
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
Pearson, S. M., Kietsiriroje, N., & Ajjan, R. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s229802 · Cited by 38
“5 years.(38) At week 26, 3 mg, 7 mg, and 14 mg of oral semaglutide significantly reduced HbA1c from baseline by −0.”
BackgroundDing, Y., Shi, Y., Guan, R., Yan, S., Liu, H., Wang, Z., Li, J., Wang, T., Cai, W., & Ma, G. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2023.107031 · Cited by 31
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
Al‐Sadawi, M., Aslam, F. M., Tao, M., Alsaiqali, M., Almasry, I. O., Fan, R., Rashba, E. J., & Singh, A. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101218 · Cited by 34
Jain, A., Reichert, S. M., Amadid, H., Braae, U. C., Bradley, R. M., Kim, J. W., Soo, V., & Yale, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15493 · Cited by 31
Arai, T., Atsukawa, M., Tsubota, A., Oikawa, T., Tada, T., Matsuura, K., Ishikawa, T., Abe, H., Kato, K., Morishita, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15898 · Cited by 30
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
“Beyond its well-documented effects on glycemic control, including reduced risk of progression to diabetes, and weight loss in individuals with and without T2D [5–8], semaglutide has been shown to reduce major adverse CV events (MACE) in adults with and without T2D [9–13].”
InfluentialManagement of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 41
“In the PIONEER 1 trial, which evaluated oral semaglutide vs placebo in patients treated with diet and exercise, rates of any AE were 58%, 53%, and 57% with use of oral semaglutide 3, 7, and 14 mg, respectively, and 56% with placebo use.(25) The corresponding incidence rates of serious AEs were 3%, 2%, and 1% with oral…”
BackgroundMethodInfluentialCandido, R., Gaiotti, S., Giudici, F., Toffoli, B., Luca, F. D., Velardi, V., Petrucco, A., Gottardi, C., Manca, E., Buda, I., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186052 · Cited by 29
“in the PIONEER 1 study [12], where gastrointestinal symptoms were the most frequent complaint, which was reported by a proportion of patients ranging from 5.”
Wu, W., Tong, H.-M., Li, Y., & Cui, J. (2023) · Endocrine · doi:10.1007/s12020-023-03636-9 · Cited by 30
Małyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 30
“…change at the end of the study; Table S2: Risk of bias assessment; Table S3: Certainty assessment; Figure S2: Pairwise meta-analysis, GLP-1RA vs. DPP-4i [21,28,29,47,64,72]; Figure S3: Pairwise meta-analysis, Semaglutide vs. placebo [6,20,22,61–63, 71 , 73 , 74 ] ; Figure S4: Pairwise meta-analysis”
BackgroundAntza, C., Nirantharakumar, K., Doundoulakis, I., Tahrani, A. A., & Toulis, K. A. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s166765 · Cited by 30
“Further results and secondary end points are expected to be published after the completion of PIONEER 1 trial.(42)”
BackgroundJordy, A. B., Albayaty, M., Breitschaft, A., Anderson, T. W., Christiansen, E., Houshmand-Øregaard, A., Manigandan, E., & Bækdal, T. A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00976-x · Cited by 27
Self-citationKokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
Goldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
Marassi, M., & Fadini, G. P. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.005 · Cited by 27
Liarakos, A. L., Tentolouris, A., Kokkinos, A. D., Eleftheriadou, I., & Tentolouris, N. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108390 · Cited by 30
Ji, L., Agesen, R. M., Bain, S. C., Fu, F., Gabery, S., Geng, J., Li, Y., Lu, Y., Luo, B., Pang, W., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06133-4 · Cited by 27
History of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
Xiong, S., Gou, R., Liang, X., Wu, H., Qin, S., Li, B., Luo, C., & Chen, J. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01594-7 · Cited by 26
Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
“The PIONEER trials further demonstrated that oral semaglutide significantly reduces HbA1c levels and body weight in a dose-dependent manner in patients with T2DM [37–43].”
Updike, W. H., Pane, O., Franks, R. B., Saber, F., Abdeen, F., Balazy, D. D., & Carris, N. W. (2021) · Drugs · doi:10.1007/s40265-021-01525-x · Cited by 30
Why ITT analysis is not always the answer for estimating treatment effects in clinical trials
Keene, O. N., Wright, D. N. M., Phillips, A., & Wright, M. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106494 · Cited by 26
Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey
Fletcher, C., Hefting, N., Wright, M., Bell, J., Anzures‐Cabrera, J., Wright, D. N. M., Lynggaard, H., & Schueler, A. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00402-3 · Cited by 26
Cardiometabolic medicine – the US perspective on a new subspecialty
Reiter–Brennan, C., Cainzos‐Achirica, M., Soroosh, G., Saxon, D. R., Blaha, M. J., & Eckel, R. H. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000224 · Cited by 26
Liu, Y., He, L., Han, S., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039446 · Cited by 27
Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton, S., Mosenzon, O., & Wright, E. E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798162 · Cited by 29
Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Albert, S. G., Wood, E. M., & Ahir, V. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102696 · Cited by 26
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“More recently, an oral version of semaglutide has become available ( 119 ) ( 120 , 121 ).”
BackgroundMyeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 27
van Houtum, W. H., Schrömbges, P. P. G., Amadid, H., van Bon, A. C., Braae, U. C., Hoogstraten, C., & Herrings, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01588-5 · Cited by 24
Pratley, R. E., Crowley, M. J., Gislum, M., HERTZ, C. L., Jensen, T. B., Khunti, K., Mosenzon, O., & Buse, J. B. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00994-9 · Cited by 27
“Data from PIONEER 1 were not included because oral semaglutide was given as monotherapy [12], PIONEER 2 was excluded because all patients randomised to oral semaglutide or comparator were receiving background metformin (and no other background glucose-lowering medication) [13], and PIONEER 6 was excluded because it wa…”
Self-citationYabe, D., Deenadayalan, S., Horio, H., Kaneto, H., Jensen, T. B., Terauchi, Y., Yamada, Y., & Inagaki, N. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13764 · Cited by 23
Self-citationJiao, X., Peng, P., Zhang, Q., & Shen, Y. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01319-x · Cited by 24
Zhao, T., Zheng, L., Feng, Y., Lao, M., Huang, Y., & Wu, G. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-04096-7 · Cited by 24
Tsukamoto, S., Tanaka, S., Yamada, T., Uneda, K., Azushima, K., Kinguchi, S., Wakui, H., & Tamura, K. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15312 · Cited by 28
“Oral semaglu-tide has good therapeutic efficacy 16 – 19 and may expand treatment options and lead to improved treatment adherence among patients.”
BackgroundKhalid, S. I., Massaad, E., Thomson, K. B., & Shin, J. H. (2024) · Journal of Neurosurgery Spine · doi:10.3171/2024.6.spine24141 · Cited by 25
Borner, T., Shaulson, E. D., Tinsley, I. C., Stein, L. M., Horn, C. C., Hayes, M. R., Doyle, R. P., & Jonghe, B. C. D. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14089 · Cited by 25
Singh, A. K., Singh, R., Singh, A., & Misra, A. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103024 · Cited by 22
Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis
Masson, W., Lobo, M., Barbagelata, L., Lavalle-Cobo, A., & Nogueira, J. P. (2024) · Endocrinología, Diabetes y Nutrición (English ed.) · doi:10.1016/j.endien.2024.03.012 · Cited by 22
Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data
Massy, M., Marti, S., Hammer, H. N., & Hoepner, R. (2025) · BMC Medicine · doi:10.1186/s12916-025-04031-z · Cited by 22
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 24
“The reported HbA1c reduction ranged between 0.6% and 1.1% as compared to the placebo in the Pioneer 1 trial [75], of 1.3% as compared to the 0.9% reduction for empagliflozin [76], with the highest reported reduction of 1.7% in the Pioneer 9 trial [61].”
BackgroundMethodInfluentialCatrina, S., Amadid, H., Braae, U. C., Dereke, J., Ekberg, N. R., Klanger, B., & Jansson, S. P. O. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01614-6 · Cited by 22
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
“[25] Higher doses are currently under investigation for weight management in IWO.”
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 27
“Individual trials have proven that they can effectively lead to good glycemic control and clinically significant weight loss in patients with T2D (Sorli et al., 2017; Aroda et al., 2019).”
BackgroundIncretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus
Clements, J. N., Isaacs, D. M., Hartman, R. E., & Gambill, K. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00951-6 · Cited by 22
Buse, J. B., Christensen, H. N., Harty, B. J., Mitchell, J., Soule, B. P., Zacherle, E. W., Cziraky, M. J., & Willey, V. J. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003206 · Cited by 21
Rudofsky, G., Amadid, H., Braae, U. C., Catrina, S., Kick, A., Mandavya, K., Roslind, K., Saravanan, P., van Houtum, W. H., & Jain, A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01668-6 · Cited by 22
Bain, E. K., & Bain, S. C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 20
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Central mechanisms of emesis: A role for GDF15
Borner, T., Pataro, A. M., & Jonghe, B. C. D. (2024) · Neurogastroenterology & Motility · doi:10.1111/nmo.14886 · Cited by 24
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Ishii, H., Hansen, B. B., Langer, J., & Horio, H. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00985-w · Cited by 19
Kalra, S., Das, S., & Zargar, A. H. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_522_21 · Cited by 24
Frazer, M., Swift, C., Gronroos, N. N., Sargent, A., Leszko, M., Buysman, E. K., Alvarez, S., Dunn, T. J., Noone, J. M., & Guevarra, M. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02677-w · Cited by 19
“In clinical trials, patients with an oral semaglutide dose escalated to 14 mg for 26 weeks had a mean HbA1c decrease of 1.0–1.4% [12–17].”
InfluentialMetabolic disorders in prediabetes: From mechanisms to therapeutic management
Ping, W.-X., Hu, S., Su, J., & Ouyang, S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.361 · Cited by 25
Khan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 21
Patient preferences for newer oral therapies in type 2 diabetes
Savarese, G., Sharma, A., Pang, C., Wood, R., & Soleymanlou, N. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.09.009 · Cited by 19
Meier, J. J., Granhall, C., Hövelmann, U., Navarria, A., Plum‐Mörschel, L., Ramesh, C. K., Tannapfel, A., & Kapitza, C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14632 · Cited by 19
Oral semaglutide for the treatment of obesity: a retrospective real-world study
Krajnc, M., Kuhar, N., & Koceva, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593334 · Cited by 20
Furusawa, S., Nomoto, H., Yokoyama, H., Suzuki, Y., Tsuzuki, A., Takahashi, K., Miya, A., Kameda, H., Cho, K. Y., Takeuchi, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15393 · Cited by 19
Chae, Y., Kwon, S., Nam, J. H., Kang, E., Im, J., Kim, H.-J., & Lee, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2363838 · Cited by 18
Girges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Recent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., PIONEER 1 Investigators, Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., Hudcova, M., Vesela, A., Rancova, A., Haluzik, M., Kiyosue, A., Matsuoka, O., Inoue, S., Terauchi, Y., Fukushima, Y., Ide, Y., Violante Ortiz, R. M., Morales Villegas, E., Golovach, A., Alpenidze, D., Frolova, E., Zhdanova, E., Ruyatkina, L., Ershova, O., Samoilova, Y., Zyangirova, S., Lalic, K., Lalic, N., Beljic Zivkovic, T., Ataoglu, E., Bakiner, O., Dayan, A., Sargin, M., Mert, M., Adas, M., Tabak, O., Altuntas, Y., Murray, A., Iranmanesh, A., Schlau, A., Wieskopf, B., Snyder, B., Griffin, C., Fogarty, C., Lovell, C., Allison, D., Fitz-Patrick, D., Grant, D., Klonoff, D., Williams, D., Armas, E., Palace, E., Ruoff, G., Martinez, G., Perez, G., Bays, H., Tatu, H., Maynard, J., Cedeno, J.-E., Aroda, V., Park, J., Sutton, J., Pouzar, J., Bertsch, J., Condit, J., Serje, J., Cabaccan, J., Risser, J., Frias, J., Rosenstock, J., Sivalingam, K., Maw, K., Hanson, L., Billings, L., Connery, L., Juarez, M., Lillestol, M., Fraser, N., Beckett, P., Wade, R., Gaona, R., Jackson, R., DeLuca, R., Alpizar, S., Herring, S., Stringam, S., Bauer, S., Gangi, S., Sligh, T., Jarrett, W., & Fitzgibbons, W.
- Affiliations
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Cardiometabolic Research Center, Aguascalientes, Mexico
- Novo Nordisk (Denmark) (DK)
- Institute for Clinical and Experimental Medicine and Institute for Endocrinology, Prague, Czech Republic
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-11
- Volume
- 42
- Issue
- 9
- Pages
- 1724-1732
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2951522032
- Cited by
- 493
- References
- 23
- Citations by year
- 2026: 60 · 2025: 107 · 2024: 91 · 2023: 56 · 2022: 53 · 2021: 55 · 2020: 57 · 2019: 13
- FWCI
- 36.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, monotherapy, HbA1c, glycemic control, weight loss, treatment policy estimand, gastrointestinal adverse effects, drug discontinuation, dose comparison, treatment efficacy and safety
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Diet, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.